torcetrapib/atorvastatin + atorvastatin

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hypertriglyceridemia

Conditions

Hypertriglyceridemia, Hyperlipoproteinemia Type IV

Trial Timeline

Feb 1, 2005 → Nov 1, 2006

NCT ID

NCT00134498

About torcetrapib/atorvastatin + atorvastatin

torcetrapib/atorvastatin + atorvastatin is a phase 3 stage product being developed by Pfizer for Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00134498. Target conditions include Hypertriglyceridemia, Hyperlipoproteinemia Type IV.

What happened to similar drugs?

1 of 20 similar drugs in Hypertriglyceridemia were approved

Approved (1) Terminated (0) Active (19)

🔄Placebo + Ethyl IcosapentateSumitomo PharmaPhase 3

🔄Omega-3-Acid Ethyl Esters 90 Soft Capsules + Corn OilJiangsu Hengrui MedicinePhase 3

✅rosuvastatinAstraZenecaApproved

🔄Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4gAstraZenecaPhase 3

🔄Epanova + Olive OilAstraZenecaPhase 3

🔄AZD0585 + AZD0585 placeboAstraZenecaPhase 3

🔄ABT-143 + simvastatinAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00134485	Phase 3	Completed	Mar 1, 2005	Mar 1, 2006	Hypercholesterolemia, Familial
NCT00134498	Phase 3	Completed	Feb 1, 2005	Nov 1, 2006	Hypertriglyceridemia
NCT00137462	Phase 3	Completed	Nov 1, 2004	Sep 1, 2006	Hyperlipidemia
NCT00134264	Phase 3	Terminated	Jul 1, 2004	Jun 1, 2007	Coronary Disease
NCT00136981	Phase 3	Completed	Dec 1, 2003	Nov 1, 2006	Hypercholesterolemia, Familial
NCT00134238	Phase 3	Terminated	Nov 1, 2003	Dec 1, 2006	Mixed Hyperlipidemia
NCT00134173	Phase 3	Completed	Oct 1, 2003	Sep 1, 2006	Coronary Disease

Competing Products

20 competing products in Hypertriglyceridemia

See all competitors

Product	Company	Stage	Hype Score
LY3875383 + Placebo	Eli Lilly	Phase 1	21
ZYH7 + ZYH7 + ZYH7 + Fenofibrate	Zydus Lifesciences	Phase 2	35
Solbinsiran + Placebo	Eli Lilly	Phase 2	42
Placebo + Ethyl Icosapentate	Sumitomo Pharma	Phase 3	40
Omega-3-Acid Ethyl Esters 90 Soft Capsules + Corn Oil	Jiangsu Hengrui Medicine	Phase 3	36
warfarin + omefas + omega-3-acid ethyl esters	AstraZeneca	Phase 1	29
rosuvastatin	AstraZeneca	Approved	43
Simvastatin + acetylsalicylic acid (ASA) + omefas	AstraZeneca	Phase 1	29
Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4g	AstraZeneca	Phase 3	40
Epanova (4 g) and Lovaza (4 g) + Lovaza (4 g) and Epanova (4 g)	AstraZeneca	Phase 2	35
rosuvastatin 40 mg tablet + Epanova™ QD (2 x 1 g capsules) + Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose + Multiple (20) oral doses of 2 g Vascepa® every 12 hours	AstraZeneca	Phase 1	29
placebo + omefas + omefas + omefas	AstraZeneca	Phase 2/3	38
Epanova + Lovaza	AstraZeneca	Phase 1	29
Epanova + Olive Oil	AstraZeneca	Phase 3	40
AZD0585 + AZD0585 placebo	AstraZeneca	Phase 3	40
ABT-143 + simvastatin	AstraZeneca	Phase 3	40
Maraviroc	Pfizer	Phase 1	29
Icosapent (MND-2119) + Icosapent (EPADEL CAPSULES 300)	Mochida Pharmaceutical	Phase 3	40
Icosapent	Mochida Pharmaceutical	Phase 3	40
REGN1500 + placebo	Regeneron Pharmaceuticals	Phase 1	29